MeiraGTx Holdings PLC (NASDAQ:MGTX – Get Free Report) CEO Alexandria Forbes sold 62,000 shares of the company’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $9.17, for a total transaction of $568,540.00. Following the transaction, the chief executive officer owned 1,387,695 shares in the company, valued at approximately $12,725,163.15. The trade was a 4.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Alexandria Forbes also recently made the following trade(s):
- On Tuesday, March 24th, Alexandria Forbes sold 62,000 shares of MeiraGTx stock. The shares were sold at an average price of $7.41, for a total transaction of $459,420.00.
MeiraGTx Price Performance
NASDAQ:MGTX opened at $9.58 on Thursday. MeiraGTx Holdings PLC has a one year low of $4.82 and a one year high of $11.85. The company has a market cap of $887.20 million, a PE ratio of -6.47 and a beta of 1.23. The firm has a 50-day moving average of $9.01 and a 200-day moving average of $8.29.
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on the company. Piper Sandler raised their price objective on MeiraGTx from $26.00 to $30.00 and gave the company an “overweight” rating in a research note on Wednesday, April 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of MeiraGTx in a research report on Tuesday, April 21st. Chardan Capital restated a “buy” rating and set a $35.00 price target on shares of MeiraGTx in a report on Friday, March 27th. Zacks Research raised shares of MeiraGTx from a “strong sell” rating to a “hold” rating in a research report on Monday, March 9th. Finally, Royal Bank Of Canada increased their price objective on shares of MeiraGTx from $24.00 to $25.00 and gave the company an “outperform” rating in a research note on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $25.83.
Get Our Latest Stock Report on MeiraGTx
Institutional Investors Weigh In On MeiraGTx
Several large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets raised its stake in shares of MeiraGTx by 43.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,810 shares of the company’s stock worth $31,000 after purchasing an additional 1,466 shares during the period. State of Alaska Department of Revenue bought a new position in MeiraGTx during the third quarter valued at about $33,000. Tower Research Capital LLC TRC increased its holdings in MeiraGTx by 390.9% during the second quarter. Tower Research Capital LLC TRC now owns 8,797 shares of the company’s stock worth $57,000 after buying an additional 7,005 shares during the last quarter. ProShare Advisors LLC purchased a new stake in MeiraGTx during the fourth quarter worth about $94,000. Finally, Abel Hall LLC bought a new stake in MeiraGTx in the fourth quarter worth about $98,000. 67.48% of the stock is owned by hedge funds and other institutional investors.
MeiraGTx Company Profile
MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.
The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.
Featured Stories
- Five stocks we like better than MeiraGTx
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.
